This is a parameter we can actively influence in clinical practice
Surprisingly, 1 in 7 GLP-1 users (14%) began treatment without a prescription, including 19% of millennials the highest of any generation
Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF
Risk ratios (RR) for MACE estimates according to direct (DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors against placebo) and indirect (DPP-4 inhibitors vs GLP-1RA or SGLT-2 inhibitors, and GLP-1RA vs SGLT-2 inhibitors) comparisons
But the headline conclusion of "selective fat reduction with relative preservation of lean tissue" can't hold equally across age strata, and the meta-analytic average obscures the patients we should be most concerned about
Newer combination peptides GLP-1 + GIP, and GLP-1 + GIP + glucagon are even more powerful and represent the next decade of metabolic therapeutics